Country: Australia
Bahasa: Inggeris
Sumber: Department of Health (Therapeutic Goods Administration)
Buprenorphine hydrochloride
Reckitt Benckiser Pty Ltd
Medicine Registered
SUBUTEX 1 SUBUTEX _Buprenorphine hydrochloride _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about SUBUTEX. It does not contain all the available information. All medicines have risks and benefits. Your doctor has weighed the risks of you taking SUBUTEX against the benefits you may gain and he/she believes it will help in your treatment. IF YOU HAVE ANY CONCERNS ABOUT TAKING SUBUTEX, ASK YOUR DOCTOR. KEEP THIS LEAFLET. You may want to read it again. WHAT IS SUBUTEX USED FOR? SUBUTEX is used as part of a medical, social and psychological treatment program for patients addicted to opiate drugs like heroin, morphine, oxycodone or codeine. SUBUTEX is used to help patients overcome this medical condition. SUBUTEX tablets contain the active ingredient buprenorphine hydrochloride. It acts as a substitute for opiate drugs like heroin, morphine, oxycodone or codeine and it helps withdrawal from opiate drugs over a period of time. SUBUTEX should be used exactly as prescribed by your doctor. Ask your doctor if you have any questions about why Subutex has been prescribed for you. These tablets are described as 'sublingual'. This means that the tablet should be placed under the tongue and kept there until fully dissolved, which usually occurs within 2 to 10 minutes. BEFORE YOU TAKE SUBUTEX SUBUTEX is not suitable for everyone. _WHEN YOU MUST NOT TAKE _ _SUBUTEX _ If you are under the age of 16 years. If you are allergic to buprenorphine or to any of the other ingredients in this medicine (see Product Description). If you have serious breathing problems. If you have serious problems with your liver, Baca dokumen lengkap
_ _ _Page 1 of 10 _ SUBUTEX (BUPRENORPHINE) 0.4mg, 2mg and 8mg Sublingual Tablets NAME OF THE MEDICINE SUBUTEX sublingual tablets contain buprenorphine hydrochloride. DESCRIPTION SUBUTEX is an uncoated tablet intended for sublingual administration. It is available in three dosage strengths, 0.4mg, 2mg and 8mg buprenorphine. Each tablet also contains lactose, mannitol, starch-maize, povidone, citric acid-anhydrous, sodium citrate, and magnesium stearate. Buprenorphine hydrochloride is a white powder, weakly acidic with limited solubility in water (19.5 mg /mL at 37 C, pH 4.1). Chemically, buprenorphine is 21-Cyclopropyl-7 - (S) –1- hydroxy- 1,2,2 - trimethylpropyl -6,14-_endo_ –ethano-6,7,8,14-tetrahydrooripavine hydrochloride. Buprenorphine hydrochloride has the molecular formula C 29 H 41 NO 4 HCl and the molecular weight is 504.09. The CAS number is 53152-21-9. The chemical structure of buprenorphine is: PHARMACOLOGY _PHARMACODYNAMIC PROPERTIES _ Buprenorphine is a µ (mu) opioid receptor partial agonist, (kappa) opioid receptor antagonist. Its activity in opioid maintenance treatment is attributed to its slow dissociation from the µ receptors in the brain which reduces craving for opioids and opiate withdrawal symptoms. This minimises the need of the addicted patient for illicit opiate drugs. During clinical pharmacology studies in opiate-dependent subjects, buprenorphine demonstrated a ceiling effect on a number of parameters, including positive mood, “good effect”, and respiratory depression. _ _ _PHARMACOKINETIC PROPERTIES_ ABSORPTION When taken orally, buprenorphine undergoes first-pass metabolism with N-dealkylation and glucuroconjugation in the small intestine and the liver. The use of SUBUTEX by the oral route i Baca dokumen lengkap